Nuvation Bio Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Nuvation Bio ont diminué à un taux annuel moyen de -27.1%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en à 12.2% par an. Les revenus ont augmenté de en à un taux moyen de 95.8% par an.
Informations clés
-27.09%
Taux de croissance des bénéfices
-17.68%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 5.95% |
| Taux de croissance des recettes | 95.76% |
| Rendement des fonds propres | -59.02% |
| Marge nette | -88.19% |
| Dernière mise à jour des bénéfices | 30 Jun 2026 |
Mises à jour récentes des performances passées
Recent updates
NUVB: Safusidenib Glioma Data Will Drive Future Upside Potential
Analysts have nudged their average price target for Nuvation Bio higher from about $12.33 to roughly $13.11, citing recent safusidenib trial updates, upward revisions to individual targets as high as $21, and an expanded view of the long term glioma treatment opportunity. Analyst Commentary Recent Street research on Nuvation Bio focuses heavily on safusidenib data and how that might translate into future revenue potential and stock valuation.
NUVB: Glioma Data And Lung Cancer Progress Will Shape Future Upside And Risks
Analysts have trimmed their fair value estimate for Nuvation Bio from $8.00 to $7.00 as they factor in a slightly higher discount rate, more moderate projected revenue growth, and updated views on long term profitability and future P/E, while also citing supportive safusidenib data and a revised $19 price target. Analyst Commentary on Nuvation Bio Recent research commentary on Nuvation Bio centers on updated safusidenib data and how that could influence long term valuation, especially in relation to the company’s revised fair value estimate and price target.NUVB: UK Regulatory Progress For Lead Oncology Asset Will Drive Future Upside
Analysts have adjusted their fair value estimate for Nuvation Bio to $12.33 from $10.25, citing updated assumptions on discount rates, future profitability and P/E expectations, alongside recent sector commentary around biotech earnings and capital flows. What’s in the News for Nuvation Bio Nuvation Bio reported that partner Eisai’s Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non small cell lung cancer was validated by the UK Medicines and Healthcare products Regulatory Agency, moving the therapy into formal UK regulatory review (source: company announcement and partner Eisai).
NUVB: Convertible Notes Raise Will Support Advancing Lead Oncology Portfolio
Analysts have lifted their price target on Nuvation Bio from about $16.80 to roughly $19.70, reflecting updated assumptions for revenue growth, profit margins, discount rate and future P/E that they see as better aligned with the company’s current outlook. What’s in the News for Nuvation Bio Nuvation Bio plans to raise up to US$230 million through a convertible senior notes offering maturing in 2032.Nuvation Bio: David Hung's Latest Venture Looks Undervalued At Current Level
Summary I initiate coverage of Nuvation Bio with a Moderate Buy, citing undervaluation based on two value-driving oncology assets. NUVB's fundamentals hinge on Ibtrozi (taletrectinib), a next-gen ROS1 inhibitor now commercial, and safusidenib, a late-stage mutant IDH1 inhibitor. My sum-of-the-parts analysis yields a $5.6/share fair value, with further upside from M&A potential, re-rating anchored on recent M&A activity, and milestone payments. Risks include Ibtrozi's revenue ramp, patent runway, and clinical uncertainty for safusidenib, but a strong balance sheet limits near-term dilution. Read the full article on Seeking AlphaResults: Nuvation Bio Inc. Confounded Analyst Expectations With A Surprise Profit
Investors in Nuvation Bio Inc. ( NYSE:NUVB ) had a good week, as its shares rose 8.1% to close at US$4.81 following the...Is Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst
Summary Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for NSCLC. The FDA has accepted Nuvation's New Drug Application for the drug, assigning it priority review and a PDUFA date of June 23, 2025. Taletrectinib shows clearly superior clinical data compared to rivals, with a potential market opportunity of ~$3.8bn by its fourth year, despite current market skepticism. Concerns include reliance on Chinese study data and competition from established pharma giants, but Nuvation's cash reserves suggest readiness for a wide-scale launch. Ahead of the PDUFA date, Nuvation presents a speculative investment opportunity, given it is potentially undervalued with a "blockbuster-in-waiting" drug candidate so close to approval, and further promising pipeline assets. Read the full article on Seeking AlphaIs Nuvation Bio (NYSE:NUVB) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Summary Nuvation Bio's Taletrectinib shows promising data in phase 2 trials for ROS1-positive NSCLC, outperforming current market leaders in key metrics like DOR and PFS. Despite a small target market, Taletrectinib's potential $1bn market opportunity and strong financials make NUVB a compelling investment ahead of its PDUFA. Risks include a competitive landscape with established drugs and emerging rivals like NVL-520, which could impact market share. With solid leadership and a strong cash position, NUVB is well-positioned for growth, making it a stock to watch closely. Read the full article on Seeking AlphaNuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Summary Nuvation Bio transitioned from early-stage to late-stage biotech with a near-approval, sitting at a $700 million market cap. The main project is taletrectinib, a novel ROS1 inhibitor with high response rates observed in studies, aiming for NDA filing. Financially stable with cash runway of 12-13 quarters, potential for accelerated approval of taletrectinib, but uncertainty in market adoption. Read the full article on Seeking AlphaIs Nuvation Bio (NYSE:NUVB) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Nuvation Bio: A Potentially Transformative Acquisition
Summary Nuvation Bio stock has been on a roll since late October, as the shares have roughly tripled since then. The main driver of this rally is the potentially transformative acquisition of AnHeart Therapeutics. This greatly enhanced Nuvation's pipeline and prospects. Analyst firms have a universally positive outlook on the company and its equity as well. In addition, Nuvation is well-funded, with the majority of the stock's market cap represented in cash and marketable securities on the company's balance sheet. An analysis around Nuvation Bio follows in the paragraphs below. Read the full article on Seeking AlphaNuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Summary Nuvation Bio has acquired an advanced pipeline candidate, taletrectinib, leading to a surge in market cap approaching $1 billion. Taletrectinib has shown promising clinical activity in treating ROS1-positive non-small cell lung cancer and has Breakthrough Therapy Designation. Nuvation Bio also now has other pipeline candidates, including safusidenib and NUV-868, and has sufficient liquid assets to fund operations for years without help. Read the full article on Seeking AlphaVentilation des recettes et des dépenses
Comment Nuvation Bio gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 26 | 170 | -150 | 159 | 129 |
| 31 Mar 26 | 143 | -146 | 154 | 126 |
| 31 Dec 25 | 63 | -205 | 152 | 115 |
| 30 Sep 25 | 27 | -217 | 137 | 110 |
| 30 Jun 25 | 14 | -203 | 120 | 109 |
| 31 Mar 25 | 11 | -606 | 97 | 111 |
| 31 Dec 24 | 8 | -568 | 69 | 99 |
| 30 Sep 24 | 2 | -532 | 49 | 85 |
| 30 Jun 24 | 1 | -511 | 37 | 76 |
| 31 Mar 24 | 0 | -69 | 28 | 65 |
| 31 Dec 23 | 0 | -76 | 29 | 71 |
| 30 Sep 23 | 0 | -83 | 31 | 73 |
| 30 Jun 23 | 0 | -90 | 31 | 76 |
| 31 Mar 23 | 0 | -105 | 32 | 86 |
| 31 Dec 22 | 0 | -104 | 32 | 88 |
| 30 Sep 22 | 0 | -108 | 32 | 89 |
| 30 Jun 22 | 0 | -103 | 30 | 85 |
| 31 Mar 22 | 0 | -88 | 27 | 70 |
| 31 Dec 21 | 0 | -87 | 24 | 65 |
| 30 Sep 21 | 0 | -75 | 21 | 56 |
| 30 Jun 21 | 0 | -64 | 18 | 48 |
| 31 Mar 21 | 0 | -53 | 14 | 41 |
| 31 Dec 20 | 0 | -42 | 11 | 33 |
| 30 Sep 20 | 0 | -38 | 8 | 32 |
| 30 Jun 20 | 0 | -32 | 7 | 27 |
| 31 Mar 20 | 0 | -33 | 7 | 26 |
| 31 Dec 19 | 0 | -34 | 7 | 25 |
Des revenus de qualité: NUVB n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: NUVB n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: NUVB n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 27.1% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de NUVB au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: NUVB n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 1% ).
Rendement des fonds propres
ROE élevé: NUVB a un retour sur capitaux propres négatif ( -59.02% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/24 11:55 |
| Cours de l'action en fin de journée | 2026/08/21 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Nuvation Bio Inc. est couverte par 16 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Clarence Powell | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Li Wang Watsek | Cantor Fitzgerald & Co. |